Table 2.
Multivariate Analysis Comparing Allogeneic HSCT Recipients (n = 282) Who Developed >1 MBI-LCBI and CLABSI in the First Year Post-Transplant versus Those Who Did Not
| Variable | Allogeneic Recipients Who Developed ≥1 MBI-LCBI
|
Allogeneic Recipients Who Developed ≥1 CLABSI
|
||
|---|---|---|---|---|
| Multivariate
|
Multivariate
|
|||
| OR | P | OR | P | |
| Diagnosi | ||||
| Marrow failure | 1 | – | 1 | – |
| Immunodeficiency | 1.93 | .15 | 4.42 | .0061 |
| Malignancy | 1.24 | .68 | 2.14 | .21 |
| Benign hematology | 2.59 | .14 | 1.74 | .54 |
| Genetic | 2.62 | .19 | 1.61 | .67 |
| RIC | 1.96 | .015 | 1.27 | .51 |
| Unrelated donor | 1.07 | .86 | .88 | .73 |
| Full match | .68 | .23 | .98 | .96 |
| Grades II–IV acute GVHD | 1.67 | .07 | 1.20 | .57 |
| TA-TMA | 2.94 | .0004 | 2.97 | .0019 |
Values in bold type indicate variables included in final model. RIC indicates reduced-intensity conditioning.
*
Diagnosis variables were considered for exclusion or inclusion together.